| Suzanne Michelle Homan, MD/PHD | |
|
47 New Scotland Ave, Albany, NY 12208-3412 | |
| (218) 262-5926 | |
| (518) 262-5861 |
| Full Name | Suzanne Michelle Homan |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 25 Years |
| Location | 47 New Scotland Ave, Albany, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316198369 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 246136 (New York) | Secondary |
| 207ZH0000X | Pathology - Hematology | 246136 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Berkshire Medical Center | Pittsfield, MA | Hospital |
| Fairview Hospital | Great barrington, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Massachusetts Pathology Services, Pc | 3072544907 | 5 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.
A single high-risk human papilloma virus-positive test can predict the development of cervical neoplasias for up to 18 years, a large, American study shows.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
› Verified 2 days ago
| Entity Name | Berkshire Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295765261 PECOS PAC ID: 1355232711 Enrollment ID: O20040324000088 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.
A single high-risk human papilloma virus-positive test can predict the development of cervical neoplasias for up to 18 years, a large, American study shows.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
› Verified 2 days ago
| Entity Name | Western Massachusetts Pathology Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295812360 PECOS PAC ID: 3072544907 Enrollment ID: O20050830000661 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.
A single high-risk human papilloma virus-positive test can predict the development of cervical neoplasias for up to 18 years, a large, American study shows.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Suzanne Michelle Homan, MD/PHD 47 New Scotland Ave, Albany, NY 12208-3412 Ph: (218) 262-5926 | Suzanne Michelle Homan, MD/PHD 47 New Scotland Ave, Albany, NY 12208-3412 Ph: (218) 262-5926 |
News Archive
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.
A single high-risk human papilloma virus-positive test can predict the development of cervical neoplasias for up to 18 years, a large, American study shows.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
› Verified 2 days ago
Dr. Syed Mohsin Ali Gilani, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave # Mc-81, Albany, NY 12208 Phone: 518-262-3661 | |
Julie Youngs, MD Pathology Medicare: Medicare Enrolled Practice Location: 43 New Scotland Ave # F117, Albany, NY 12208 Phone: 518-262-0463 | |
Dr. Bradley Gornstein, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, St. Peter's Hospital, Albany, NY 12208 Phone: 518-525-1550 | |
Dr. Russel E Newkirk, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 315 S Manning Blvd, Maplewood Pathology, Albany, NY 12208 Phone: 518-525-1474 | |
Dr. Jeffrey D Hubbard, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 315 S Manning Blvd, Maplewood Pathology, Albany, NY 12208 Phone: 518-525-1474 | |
Llewellyn Foulke, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Albany, NY 12208 Phone: 518-262-3738 | |
Tipu Nazeer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Albany, NY 12208 Phone: 518-262-3738 |